nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobupivacaine—Wound discharge increased—Capecitabine—esophageal cancer	0.0506	0.0614	CcSEcCtD
Levobupivacaine—Apprehension—Cisplatin—esophageal cancer	0.0258	0.0313	CcSEcCtD
Levobupivacaine—Wound secretion—Capecitabine—esophageal cancer	0.0251	0.0305	CcSEcCtD
Levobupivacaine—CNS toxicity—Methotrexate—esophageal cancer	0.0235	0.0286	CcSEcCtD
Levobupivacaine—Cranial nerve paralysis—Methotrexate—esophageal cancer	0.0235	0.0286	CcSEcCtD
Levobupivacaine—Paraplegia—Methotrexate—esophageal cancer	0.0201	0.0243	CcSEcCtD
Levobupivacaine—Extravasation—Carboplatin—esophageal cancer	0.0193	0.0234	CcSEcCtD
Levobupivacaine—Diplegia—Methotrexate—esophageal cancer	0.0187	0.0227	CcSEcCtD
Levobupivacaine—Monoplegia—Methotrexate—esophageal cancer	0.0175	0.0213	CcSEcCtD
Levobupivacaine—Neurological symptom—Cisplatin—esophageal cancer	0.0164	0.0199	CcSEcCtD
Levobupivacaine—Meningism—Methotrexate—esophageal cancer	0.0156	0.019	CcSEcCtD
Levobupivacaine—Arachnoiditis—Methotrexate—esophageal cancer	0.0149	0.018	CcSEcCtD
Levobupivacaine—Hypoaesthesia oral—Capecitabine—esophageal cancer	0.014	0.0169	CcSEcCtD
Levobupivacaine—Neurotoxicity—Cisplatin—esophageal cancer	0.0128	0.0155	CcSEcCtD
Levobupivacaine—Sensory disturbance—Capecitabine—esophageal cancer	0.0118	0.0143	CcSEcCtD
Levobupivacaine—Meningitis aseptic—Methotrexate—esophageal cancer	0.0115	0.014	CcSEcCtD
Levobupivacaine—Slurred speech—Cisplatin—esophageal cancer	0.0111	0.0134	CcSEcCtD
Levobupivacaine—Shivering—Capecitabine—esophageal cancer	0.00979	0.0119	CcSEcCtD
Levobupivacaine—Neurotoxicity—Capecitabine—esophageal cancer	0.0094	0.0114	CcSEcCtD
Levobupivacaine—Drug hypersensitivity—Capecitabine—esophageal cancer	0.00905	0.011	CcSEcCtD
Levobupivacaine—Dysaesthesia—Capecitabine—esophageal cancer	0.00843	0.0102	CcSEcCtD
Levobupivacaine—Depressed mood—Capecitabine—esophageal cancer	0.00815	0.00989	CcSEcCtD
Levobupivacaine—Prurigo—Capecitabine—esophageal cancer	0.0079	0.00958	CcSEcCtD
Levobupivacaine—Paraesthesia oral—Capecitabine—esophageal cancer	0.00778	0.00943	CcSEcCtD
Levobupivacaine—Swelling face—Capecitabine—esophageal cancer	0.00766	0.00929	CcSEcCtD
Levobupivacaine—Paresis—Methotrexate—esophageal cancer	0.00744	0.00902	CcSEcCtD
Levobupivacaine—Neurotoxicity—Methotrexate—esophageal cancer	0.007	0.00849	CcSEcCtD
Levobupivacaine—Sneezing—Capecitabine—esophageal cancer	0.00659	0.00799	CcSEcCtD
Levobupivacaine—Lidocaine—EGFR—esophageal cancer	0.00606	0.472	CrCbGaD
Levobupivacaine—Infection—Carboplatin—esophageal cancer	0.00598	0.00725	CcSEcCtD
Levobupivacaine—Neck stiffness—Methotrexate—esophageal cancer	0.0057	0.00691	CcSEcCtD
Levobupivacaine—Extravasation—Cisplatin—esophageal cancer	0.00567	0.00688	CcSEcCtD
Levobupivacaine—Nuchal rigidity—Methotrexate—esophageal cancer	0.00523	0.00635	CcSEcCtD
Levobupivacaine—Dysarthria—Cisplatin—esophageal cancer	0.00523	0.00634	CcSEcCtD
Levobupivacaine—Ileus—Capecitabine—esophageal cancer	0.00515	0.00625	CcSEcCtD
Levobupivacaine—Pain—Carboplatin—esophageal cancer	0.00514	0.00624	CcSEcCtD
Levobupivacaine—Lidocaine—CYP2A6—esophageal cancer	0.00495	0.385	CrCbGaD
Levobupivacaine—Hyperkalaemia—Cisplatin—esophageal cancer	0.00486	0.00589	CcSEcCtD
Levobupivacaine—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00476	0.00577	CcSEcCtD
Levobupivacaine—Body temperature increased—Carboplatin—esophageal cancer	0.00476	0.00577	CcSEcCtD
Levobupivacaine—Fungal infection—Capecitabine—esophageal cancer	0.00472	0.00573	CcSEcCtD
Levobupivacaine—Neuropathy—Cisplatin—esophageal cancer	0.00464	0.00563	CcSEcCtD
Levobupivacaine—CYP1A2—Sulindac Metabolic Pathway—CYP1B1—esophageal cancer	0.00447	0.0275	CbGpPWpGaD
Levobupivacaine—Rigors—Capecitabine—esophageal cancer	0.00447	0.00542	CcSEcCtD
Levobupivacaine—Extrasystoles—Capecitabine—esophageal cancer	0.00433	0.00525	CcSEcCtD
Levobupivacaine—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00406	0.00493	CcSEcCtD
Levobupivacaine—Skin discolouration—Capecitabine—esophageal cancer	0.00404	0.0049	CcSEcCtD
Levobupivacaine—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00404	0.0049	CcSEcCtD
Levobupivacaine—Hypocalcaemia—Capecitabine—esophageal cancer	0.00398	0.00483	CcSEcCtD
Levobupivacaine—Paralysis—Methotrexate—esophageal cancer	0.00391	0.00474	CcSEcCtD
Levobupivacaine—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00385	0.00467	CcSEcCtD
Levobupivacaine—Dysarthria—Capecitabine—esophageal cancer	0.00385	0.00467	CcSEcCtD
Levobupivacaine—CYP1A2—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00376	0.0231	CbGpPWpGaD
Levobupivacaine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00371	0.0045	CcSEcCtD
Levobupivacaine—Neck pain—Capecitabine—esophageal cancer	0.00369	0.00448	CcSEcCtD
Levobupivacaine—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00367	0.0226	CbGpPWpGaD
Levobupivacaine—Blood pressure increased—Capecitabine—esophageal cancer	0.00365	0.00442	CcSEcCtD
Levobupivacaine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00352	0.00427	CcSEcCtD
Levobupivacaine—Urinary incontinence—Capecitabine—esophageal cancer	0.00352	0.00427	CcSEcCtD
Levobupivacaine—Fungal infection—Methotrexate—esophageal cancer	0.00352	0.00426	CcSEcCtD
Levobupivacaine—Neuropathy—Capecitabine—esophageal cancer	0.00342	0.00415	CcSEcCtD
Levobupivacaine—Blood creatinine increased—Cisplatin—esophageal cancer	0.00336	0.00408	CcSEcCtD
Levobupivacaine—CYP1A2—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00331	0.0204	CbGpPWpGaD
Levobupivacaine—CYP1A2—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.0033	0.0203	CbGpPWpGaD
Levobupivacaine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00328	0.00398	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00323	0.00392	CcSEcCtD
Levobupivacaine—Apnoea—Methotrexate—esophageal cancer	0.0032	0.00388	CcSEcCtD
Levobupivacaine—Extravasation—Methotrexate—esophageal cancer	0.00311	0.00377	CcSEcCtD
Levobupivacaine—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00307	0.0189	CbGpPWpGaD
Levobupivacaine—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00303	0.00367	CcSEcCtD
Levobupivacaine—Sweating increased—Cisplatin—esophageal cancer	0.00302	0.00367	CcSEcCtD
Levobupivacaine—Bone disorder—Methotrexate—esophageal cancer	0.00301	0.00364	CcSEcCtD
Levobupivacaine—Skin discolouration—Methotrexate—esophageal cancer	0.00301	0.00364	CcSEcCtD
Levobupivacaine—Vascular purpura—Capecitabine—esophageal cancer	0.00296	0.00359	CcSEcCtD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.0029	0.0179	CbGpPWpGaD
Levobupivacaine—Dysarthria—Methotrexate—esophageal cancer	0.00287	0.00348	CcSEcCtD
Levobupivacaine—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00279	0.0172	CbGpPWpGaD
Levobupivacaine—Respiratory failure—Methotrexate—esophageal cancer	0.00276	0.00335	CcSEcCtD
Levobupivacaine—Purpura—Capecitabine—esophageal cancer	0.00275	0.00333	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00271	0.00329	CcSEcCtD
Levobupivacaine—Lethargy—Capecitabine—esophageal cancer	0.0027	0.00328	CcSEcCtD
Levobupivacaine—Diplopia—Capecitabine—esophageal cancer	0.00265	0.00321	CcSEcCtD
Levobupivacaine—Osteoarthritis—Capecitabine—esophageal cancer	0.00265	0.00321	CcSEcCtD
Levobupivacaine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00262	0.00318	CcSEcCtD
Levobupivacaine—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00255	0.0157	CbGpPWpGaD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00255	0.0157	CbGpPWpGaD
Levobupivacaine—Bradycardia—Cisplatin—esophageal cancer	0.00253	0.00307	CcSEcCtD
Levobupivacaine—Cardiac arrest—Capecitabine—esophageal cancer	0.00252	0.00305	CcSEcCtD
Levobupivacaine—Urinary retention—Capecitabine—esophageal cancer	0.00252	0.00305	CcSEcCtD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—esophageal cancer	0.00251	0.0154	CbGpPWpGaD
Levobupivacaine—Blood creatinine increased—Capecitabine—esophageal cancer	0.00248	0.00301	CcSEcCtD
Levobupivacaine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00242	0.00293	CcSEcCtD
Levobupivacaine—Pulmonary oedema—Methotrexate—esophageal cancer	0.00242	0.00293	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00238	0.00289	CcSEcCtD
Levobupivacaine—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00235	0.0144	CbGpPWpGaD
Levobupivacaine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00233	0.00283	CcSEcCtD
Levobupivacaine—Muscular weakness—Capecitabine—esophageal cancer	0.00233	0.00283	CcSEcCtD
Levobupivacaine—CYP1A2—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00232	0.0143	CbGpPWpGaD
Levobupivacaine—Tinnitus—Cisplatin—esophageal cancer	0.00232	0.00281	CcSEcCtD
Levobupivacaine—Flushing—Cisplatin—esophageal cancer	0.00231	0.0028	CcSEcCtD
Levobupivacaine—Cardiac disorder—Cisplatin—esophageal cancer	0.00231	0.0028	CcSEcCtD
Levobupivacaine—Abdominal distension—Capecitabine—esophageal cancer	0.0023	0.00279	CcSEcCtD
Levobupivacaine—Dysphagia—Capecitabine—esophageal cancer	0.00229	0.00277	CcSEcCtD
Levobupivacaine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00225	0.0139	CbGpPWpGaD
Levobupivacaine—Bronchospasm—Capecitabine—esophageal cancer	0.00225	0.00273	CcSEcCtD
Levobupivacaine—Sweating increased—Capecitabine—esophageal cancer	0.00223	0.0027	CcSEcCtD
Levobupivacaine—Arrhythmia—Cisplatin—esophageal cancer	0.00222	0.00269	CcSEcCtD
Levobupivacaine—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00218	0.0134	CbGpPWpGaD
Levobupivacaine—Erythema—Cisplatin—esophageal cancer	0.00216	0.00262	CcSEcCtD
Levobupivacaine—Malnutrition—Cisplatin—esophageal cancer	0.00216	0.00262	CcSEcCtD
Levobupivacaine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00215	0.0132	CbGpPWpGaD
Levobupivacaine—Flatulence—Cisplatin—esophageal cancer	0.00213	0.00258	CcSEcCtD
Levobupivacaine—CYP1A2—Estrogen Receptor Pathway—CYP1B1—esophageal cancer	0.00208	0.0128	CbGpPWpGaD
Levobupivacaine—Muscle spasms—Cisplatin—esophageal cancer	0.00208	0.00252	CcSEcCtD
Levobupivacaine—Infestation—Capecitabine—esophageal cancer	0.00204	0.00247	CcSEcCtD
Levobupivacaine—Infestation NOS—Capecitabine—esophageal cancer	0.00204	0.00247	CcSEcCtD
Levobupivacaine—Vision blurred—Cisplatin—esophageal cancer	0.00204	0.00247	CcSEcCtD
Levobupivacaine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00204	0.00247	CcSEcCtD
Levobupivacaine—Tremor—Cisplatin—esophageal cancer	0.00203	0.00246	CcSEcCtD
Levobupivacaine—Lethargy—Methotrexate—esophageal cancer	0.00201	0.00244	CcSEcCtD
Levobupivacaine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00201	0.0124	CbGpPWpGaD
Levobupivacaine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.002	0.00242	CcSEcCtD
Levobupivacaine—Anaemia—Cisplatin—esophageal cancer	0.002	0.00242	CcSEcCtD
Levobupivacaine—Urinary tract infection—Capecitabine—esophageal cancer	0.00198	0.0024	CcSEcCtD
Levobupivacaine—Osteoarthritis—Methotrexate—esophageal cancer	0.00197	0.00239	CcSEcCtD
Levobupivacaine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00195	0.012	CbGpPWpGaD
Levobupivacaine—Haematuria—Capecitabine—esophageal cancer	0.00194	0.00236	CcSEcCtD
Levobupivacaine—Convulsion—Cisplatin—esophageal cancer	0.00187	0.00227	CcSEcCtD
Levobupivacaine—Bradycardia—Capecitabine—esophageal cancer	0.00186	0.00226	CcSEcCtD
Levobupivacaine—Lidocaine—ABCB1—esophageal cancer	0.00184	0.143	CrCbGaD
Levobupivacaine—Anxiety—Cisplatin—esophageal cancer	0.00183	0.00222	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00183	0.00222	CcSEcCtD
Levobupivacaine—CYP1A2—Xenobiotics—CYP2A6—esophageal cancer	0.00183	0.0112	CbGpPWpGaD
Levobupivacaine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00182	0.00221	CcSEcCtD
Levobupivacaine—Oedema peripheral—Capecitabine—esophageal cancer	0.0018	0.00219	CcSEcCtD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00179	0.011	CbGpPWpGaD
Levobupivacaine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00176	0.00214	CcSEcCtD
Levobupivacaine—Oedema—Cisplatin—esophageal cancer	0.00176	0.00214	CcSEcCtD
Levobupivacaine—CYP1A2—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00176	0.0108	CbGpPWpGaD
Levobupivacaine—Infection—Cisplatin—esophageal cancer	0.00175	0.00213	CcSEcCtD
Levobupivacaine—Nervous system disorder—Cisplatin—esophageal cancer	0.00173	0.0021	CcSEcCtD
Levobupivacaine—Tachycardia—Cisplatin—esophageal cancer	0.00172	0.00209	CcSEcCtD
Levobupivacaine—Skin disorder—Cisplatin—esophageal cancer	0.00171	0.00208	CcSEcCtD
Levobupivacaine—Tinnitus—Capecitabine—esophageal cancer	0.00171	0.00207	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00171	0.00207	CcSEcCtD
Levobupivacaine—Cardiac disorder—Capecitabine—esophageal cancer	0.0017	0.00206	CcSEcCtD
Levobupivacaine—Flushing—Capecitabine—esophageal cancer	0.0017	0.00206	CcSEcCtD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00169	0.0104	CbGpPWpGaD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00168	0.0103	CbGpPWpGaD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00168	0.0103	CbGpPWpGaD
Levobupivacaine—Hypotension—Cisplatin—esophageal cancer	0.00165	0.002	CcSEcCtD
Levobupivacaine—Chills—Capecitabine—esophageal cancer	0.00164	0.00199	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—PFN1—esophageal cancer	0.00164	0.0101	CbGpPWpGaD
Levobupivacaine—Arrhythmia—Capecitabine—esophageal cancer	0.00164	0.00198	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00161	0.00195	CcSEcCtD
Levobupivacaine—Mental disorder—Capecitabine—esophageal cancer	0.0016	0.00195	CcSEcCtD
Levobupivacaine—CYP1A2—Estrogen metabolism—CYP1B1—esophageal cancer	0.0016	0.00986	CbGpPWpGaD
Levobupivacaine—Erythema—Capecitabine—esophageal cancer	0.00159	0.00193	CcSEcCtD
Levobupivacaine—Malnutrition—Capecitabine—esophageal cancer	0.00159	0.00193	CcSEcCtD
Levobupivacaine—Paraesthesia—Cisplatin—esophageal cancer	0.00158	0.00192	CcSEcCtD
Levobupivacaine—SCN10A—Axon guidance—PFN1—esophageal cancer	0.00158	0.00971	CbGpPWpGaD
Levobupivacaine—Dyspnoea—Cisplatin—esophageal cancer	0.00157	0.00191	CcSEcCtD
Levobupivacaine—Flatulence—Capecitabine—esophageal cancer	0.00157	0.0019	CcSEcCtD
Levobupivacaine—Back pain—Capecitabine—esophageal cancer	0.00154	0.00187	CcSEcCtD
Levobupivacaine—Decreased appetite—Cisplatin—esophageal cancer	0.00153	0.00186	CcSEcCtD
Levobupivacaine—Muscle spasms—Capecitabine—esophageal cancer	0.00153	0.00186	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00152	0.00185	CcSEcCtD
Levobupivacaine—Infestation NOS—Methotrexate—esophageal cancer	0.00152	0.00184	CcSEcCtD
Levobupivacaine—Infestation—Methotrexate—esophageal cancer	0.00152	0.00184	CcSEcCtD
Levobupivacaine—Drowsiness—Methotrexate—esophageal cancer	0.00152	0.00184	CcSEcCtD
Levobupivacaine—Pain—Cisplatin—esophageal cancer	0.00151	0.00183	CcSEcCtD
Levobupivacaine—Vision blurred—Capecitabine—esophageal cancer	0.0015	0.00182	CcSEcCtD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.0015	0.0092	CbGpPWpGaD
Levobupivacaine—Tremor—Capecitabine—esophageal cancer	0.00149	0.00181	CcSEcCtD
Levobupivacaine—Anaemia—Capecitabine—esophageal cancer	0.00147	0.00179	CcSEcCtD
Levobupivacaine—Sweating—Methotrexate—esophageal cancer	0.00146	0.00177	CcSEcCtD
Levobupivacaine—Feeling abnormal—Cisplatin—esophageal cancer	0.00145	0.00176	CcSEcCtD
Levobupivacaine—Haematuria—Methotrexate—esophageal cancer	0.00145	0.00176	CcSEcCtD
Levobupivacaine—Syncope—Capecitabine—esophageal cancer	0.00143	0.00173	CcSEcCtD
Levobupivacaine—CYP1A2—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00142	0.00872	CbGpPWpGaD
Levobupivacaine—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00141	0.00868	CbGpPWpGaD
Levobupivacaine—Palpitations—Capecitabine—esophageal cancer	0.00141	0.00171	CcSEcCtD
Levobupivacaine—Loss of consciousness—Capecitabine—esophageal cancer	0.0014	0.0017	CcSEcCtD
Levobupivacaine—Body temperature increased—Cisplatin—esophageal cancer	0.0014	0.00169	CcSEcCtD
Levobupivacaine—Cough—Capecitabine—esophageal cancer	0.00139	0.00169	CcSEcCtD
Levobupivacaine—Hypertension—Capecitabine—esophageal cancer	0.00138	0.00167	CcSEcCtD
Levobupivacaine—Arthralgia—Capecitabine—esophageal cancer	0.00136	0.00165	CcSEcCtD
Levobupivacaine—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00136	0.00835	CbGpPWpGaD
Levobupivacaine—Anxiety—Capecitabine—esophageal cancer	0.00135	0.00164	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00135	0.00163	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—CFL1—esophageal cancer	0.00133	0.00816	CbGpPWpGaD
Levobupivacaine—Confusional state—Capecitabine—esophageal cancer	0.00131	0.00159	CcSEcCtD
Levobupivacaine—Oedema—Capecitabine—esophageal cancer	0.0013	0.00158	CcSEcCtD
Levobupivacaine—Hypersensitivity—Cisplatin—esophageal cancer	0.0013	0.00158	CcSEcCtD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00129	0.00797	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00129	0.00797	CbGpPWpGaD
Levobupivacaine—Infection—Capecitabine—esophageal cancer	0.00129	0.00157	CcSEcCtD
Levobupivacaine—Shock—Capecitabine—esophageal cancer	0.00128	0.00155	CcSEcCtD
Levobupivacaine—SCN10A—Axon guidance—CFL1—esophageal cancer	0.00128	0.00786	CbGpPWpGaD
Levobupivacaine—Nervous system disorder—Capecitabine—esophageal cancer	0.00128	0.00155	CcSEcCtD
Levobupivacaine—Tinnitus—Methotrexate—esophageal cancer	0.00127	0.00154	CcSEcCtD
Levobupivacaine—Tachycardia—Capecitabine—esophageal cancer	0.00127	0.00154	CcSEcCtD
Levobupivacaine—Asthenia—Cisplatin—esophageal cancer	0.00127	0.00154	CcSEcCtD
Levobupivacaine—Cardiac disorder—Methotrexate—esophageal cancer	0.00127	0.00153	CcSEcCtD
Levobupivacaine—Skin disorder—Capecitabine—esophageal cancer	0.00126	0.00153	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00126	0.00153	CcSEcCtD
Levobupivacaine—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00124	0.00761	CbGpPWpGaD
Levobupivacaine—Chills—Methotrexate—esophageal cancer	0.00122	0.00148	CcSEcCtD
Levobupivacaine—Hypotension—Capecitabine—esophageal cancer	0.00122	0.00147	CcSEcCtD
Levobupivacaine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00121	0.00745	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Cisplatin—esophageal cancer	0.00121	0.00146	CcSEcCtD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.0012	0.00739	CbGpPWpGaD
Levobupivacaine—Mental disorder—Methotrexate—esophageal cancer	0.00119	0.00145	CcSEcCtD
Levobupivacaine—Erythema—Methotrexate—esophageal cancer	0.00119	0.00144	CcSEcCtD
Levobupivacaine—Malnutrition—Methotrexate—esophageal cancer	0.00119	0.00144	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00119	0.00144	CcSEcCtD
Levobupivacaine—Insomnia—Capecitabine—esophageal cancer	0.00118	0.00143	CcSEcCtD
Levobupivacaine—Paraesthesia—Capecitabine—esophageal cancer	0.00117	0.00142	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—PFN1—esophageal cancer	0.00117	0.00718	CbGpPWpGaD
Levobupivacaine—Dyspnoea—Capecitabine—esophageal cancer	0.00116	0.00141	CcSEcCtD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00115	0.0071	CbGpPWpGaD
Levobupivacaine—Back pain—Methotrexate—esophageal cancer	0.00115	0.00139	CcSEcCtD
Levobupivacaine—Dyspepsia—Capecitabine—esophageal cancer	0.00115	0.00139	CcSEcCtD
Levobupivacaine—Decreased appetite—Capecitabine—esophageal cancer	0.00113	0.00137	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—ACTB—esophageal cancer	0.00113	0.00693	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—PFN1—esophageal cancer	0.00113	0.00693	CbGpPWpGaD
Levobupivacaine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00112	0.00136	CcSEcCtD
Levobupivacaine—Vomiting—Cisplatin—esophageal cancer	0.00112	0.00136	CcSEcCtD
Levobupivacaine—Vision blurred—Methotrexate—esophageal cancer	0.00112	0.00136	CcSEcCtD
Levobupivacaine—Constipation—Capecitabine—esophageal cancer	0.00111	0.00135	CcSEcCtD
Levobupivacaine—Pain—Capecitabine—esophageal cancer	0.00111	0.00135	CcSEcCtD
Levobupivacaine—Anaemia—Methotrexate—esophageal cancer	0.0011	0.00133	CcSEcCtD
Levobupivacaine—CYP1A2—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00109	0.00673	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00109	0.00673	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.00109	0.00672	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—esophageal cancer	0.00109	0.00672	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ACTB—esophageal cancer	0.00109	0.00669	CbGpPWpGaD
Levobupivacaine—Feeling abnormal—Capecitabine—esophageal cancer	0.00107	0.0013	CcSEcCtD
Levobupivacaine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00107	0.00656	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00107	0.00655	CbGpPWpGaD
Levobupivacaine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00106	0.00129	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00106	0.00652	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00105	0.00647	CbGpPWpGaD
Levobupivacaine—Nausea—Cisplatin—esophageal cancer	0.00105	0.00127	CcSEcCtD
Levobupivacaine—Cough—Methotrexate—esophageal cancer	0.00104	0.00126	CcSEcCtD
Levobupivacaine—Urticaria—Capecitabine—esophageal cancer	0.00103	0.00125	CcSEcCtD
Levobupivacaine—Abdominal pain—Capecitabine—esophageal cancer	0.00103	0.00125	CcSEcCtD
Levobupivacaine—Body temperature increased—Capecitabine—esophageal cancer	0.00103	0.00125	CcSEcCtD
Levobupivacaine—Convulsion—Methotrexate—esophageal cancer	0.00103	0.00125	CcSEcCtD
Levobupivacaine—Arthralgia—Methotrexate—esophageal cancer	0.00101	0.00123	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.001	0.00122	CcSEcCtD
Levobupivacaine—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.000998	0.00614	CbGpPWpGaD
Levobupivacaine—Confusional state—Methotrexate—esophageal cancer	0.000976	0.00118	CcSEcCtD
Levobupivacaine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000969	0.00596	CbGpPWpGaD
Levobupivacaine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000968	0.00117	CcSEcCtD
Levobupivacaine—Infection—Methotrexate—esophageal cancer	0.000962	0.00117	CcSEcCtD
Levobupivacaine—Hypersensitivity—Capecitabine—esophageal cancer	0.000958	0.00116	CcSEcCtD
Levobupivacaine—Nervous system disorder—Methotrexate—esophageal cancer	0.00095	0.00115	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—CFL1—esophageal cancer	0.000946	0.00582	CbGpPWpGaD
Levobupivacaine—Skin disorder—Methotrexate—esophageal cancer	0.000941	0.00114	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000936	0.00114	CcSEcCtD
Levobupivacaine—Asthenia—Capecitabine—esophageal cancer	0.000933	0.00113	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000929	0.00571	CbGpPWpGaD
Levobupivacaine—Pruritus—Capecitabine—esophageal cancer	0.00092	0.00112	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—SOX2—esophageal cancer	0.000914	0.00562	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CFL1—esophageal cancer	0.000912	0.00561	CbGpPWpGaD
Levobupivacaine—Hypotension—Methotrexate—esophageal cancer	0.000905	0.0011	CcSEcCtD
Levobupivacaine—Diarrhoea—Capecitabine—esophageal cancer	0.00089	0.00108	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000882	0.00107	CcSEcCtD
Levobupivacaine—SCN10A—Developmental Biology—SOX2—esophageal cancer	0.000881	0.00542	CbGpPWpGaD
Levobupivacaine—Insomnia—Methotrexate—esophageal cancer	0.000876	0.00106	CcSEcCtD
Levobupivacaine—Paraesthesia—Methotrexate—esophageal cancer	0.00087	0.00105	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000863	0.00531	CbGpPWpGaD
Levobupivacaine—Dyspnoea—Methotrexate—esophageal cancer	0.000863	0.00105	CcSEcCtD
Levobupivacaine—Somnolence—Methotrexate—esophageal cancer	0.000861	0.00104	CcSEcCtD
Levobupivacaine—Dizziness—Capecitabine—esophageal cancer	0.00086	0.00104	CcSEcCtD
Levobupivacaine—Dyspepsia—Methotrexate—esophageal cancer	0.000852	0.00103	CcSEcCtD
Levobupivacaine—Decreased appetite—Methotrexate—esophageal cancer	0.000842	0.00102	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000836	0.00101	CcSEcCtD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000832	0.00512	CbGpPWpGaD
Levobupivacaine—Pain—Methotrexate—esophageal cancer	0.000828	0.001	CcSEcCtD
Levobupivacaine—Vomiting—Capecitabine—esophageal cancer	0.000827	0.001	CcSEcCtD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000822	0.00506	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000817	0.00503	CbGpPWpGaD
Levobupivacaine—Headache—Capecitabine—esophageal cancer	0.000815	0.000988	CcSEcCtD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000811	0.00499	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ACTB—esophageal cancer	0.000804	0.00495	CbGpPWpGaD
Levobupivacaine—Feeling abnormal—Methotrexate—esophageal cancer	0.000798	0.000968	CcSEcCtD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000794	0.00488	CbGpPWpGaD
Levobupivacaine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000792	0.00096	CcSEcCtD
Levobupivacaine—SCN4A—Developmental Biology—CTNNA1—esophageal cancer	0.00079	0.00486	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ACTB—esophageal cancer	0.000776	0.00477	CbGpPWpGaD
Levobupivacaine—Nausea—Capecitabine—esophageal cancer	0.000773	0.000937	CcSEcCtD
Levobupivacaine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000771	0.00474	CbGpPWpGaD
Levobupivacaine—Urticaria—Methotrexate—esophageal cancer	0.000769	0.000933	CcSEcCtD
Levobupivacaine—Body temperature increased—Methotrexate—esophageal cancer	0.000766	0.000928	CcSEcCtD
Levobupivacaine—Abdominal pain—Methotrexate—esophageal cancer	0.000766	0.000928	CcSEcCtD
Levobupivacaine—SCN10A—Developmental Biology—CTNNA1—esophageal cancer	0.000762	0.00469	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000759	0.00467	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.000757	0.00465	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000757	0.00465	CbGpPWpGaD
Levobupivacaine—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000757	0.00465	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—ABL1—esophageal cancer	0.000755	0.00464	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—EGFR—esophageal cancer	0.00075	0.00462	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000749	0.00461	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.000729	0.00448	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ABL1—esophageal cancer	0.000728	0.00448	CbGpPWpGaD
Levobupivacaine—SCN10A—L1CAM interactions—EGFR—esophageal cancer	0.000724	0.00445	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000717	0.00441	CbGpPWpGaD
Levobupivacaine—Hypersensitivity—Methotrexate—esophageal cancer	0.000713	0.000865	CcSEcCtD
Levobupivacaine—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000711	0.00438	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000708	0.00435	CbGpPWpGaD
Levobupivacaine—Asthenia—Methotrexate—esophageal cancer	0.000695	0.000843	CcSEcCtD
Levobupivacaine—Pruritus—Methotrexate—esophageal cancer	0.000685	0.000831	CcSEcCtD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000666	0.0041	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Methotrexate—esophageal cancer	0.000663	0.000804	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000654	0.00403	CbGpPWpGaD
Levobupivacaine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000643	0.00395	CbGpPWpGaD
Levobupivacaine—Dizziness—Methotrexate—esophageal cancer	0.00064	0.000777	CcSEcCtD
Levobupivacaine—Vomiting—Methotrexate—esophageal cancer	0.000616	0.000747	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000615	0.00378	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000612	0.00377	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000612	0.00376	CbGpPWpGaD
Levobupivacaine—Headache—Methotrexate—esophageal cancer	0.000607	0.000736	CcSEcCtD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000604	0.00371	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000589	0.00363	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000586	0.0036	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000584	0.00359	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000583	0.00359	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000578	0.00356	CbGpPWpGaD
Levobupivacaine—Nausea—Methotrexate—esophageal cancer	0.000575	0.000698	CcSEcCtD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000575	0.00354	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—KDR—esophageal cancer	0.000572	0.00352	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000568	0.00349	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000565	0.00348	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000563	0.00346	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MET—esophageal cancer	0.00056	0.00344	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—KDR—esophageal cancer	0.000552	0.00339	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000549	0.00338	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MET—esophageal cancer	0.00054	0.00332	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ABL1—esophageal cancer	0.000539	0.00331	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—SMAD4—esophageal cancer	0.000522	0.00321	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ABL1—esophageal cancer	0.000519	0.00319	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000505	0.00311	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—SMAD4—esophageal cancer	0.000503	0.00309	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000496	0.00305	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000493	0.00304	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000475	0.00292	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000472	0.0029	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000466	0.00287	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000466	0.00287	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000459	0.00282	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000452	0.00278	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00045	0.00277	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000444	0.00273	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000438	0.00269	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000434	0.00267	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000426	0.00262	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000421	0.00259	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000415	0.00255	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—ERBB2—esophageal cancer	0.000409	0.00252	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—KDR—esophageal cancer	0.000408	0.00251	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MET—esophageal cancer	0.000399	0.00246	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ERBB2—esophageal cancer	0.000394	0.00243	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—KDR—esophageal cancer	0.000394	0.00242	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MET—esophageal cancer	0.000385	0.00237	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—NOTCH1—esophageal cancer	0.000384	0.00237	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000383	0.00235	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000381	0.00234	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—NOTCH1—esophageal cancer	0.000371	0.00228	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00036	0.00221	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000354	0.00218	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000349	0.00215	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—CREBBP—esophageal cancer	0.000349	0.00214	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000348	0.00214	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000341	0.0021	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CREBBP—esophageal cancer	0.000336	0.00207	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.000331	0.00203	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000329	0.00202	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000327	0.00201	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000325	0.002	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000319	0.00196	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.00031	0.00191	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000298	0.00183	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ERBB2—esophageal cancer	0.000292	0.0018	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000284	0.00174	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000284	0.00174	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—EGFR—esophageal cancer	0.000284	0.00174	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ERBB2—esophageal cancer	0.000281	0.00173	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—EGFR—esophageal cancer	0.000273	0.00168	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000268	0.00165	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000263	0.00162	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00026	0.0016	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000255	0.00157	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000254	0.00156	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000252	0.00155	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.000248	0.00152	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000247	0.00152	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000244	0.0015	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000242	0.00149	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000242	0.00149	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000239	0.00147	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EP300—esophageal cancer	0.000237	0.00146	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EP300—esophageal cancer	0.000229	0.00141	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000203	0.00125	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EGFR—esophageal cancer	0.000202	0.00124	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000201	0.00123	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EGFR—esophageal cancer	0.000195	0.0012	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000191	0.00118	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000189	0.00116	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000172	0.00106	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00015	0.000921	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000133	0.000819	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000133	0.000819	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000119	0.000732	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CA1—esophageal cancer	0.000113	0.000696	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000113	0.000696	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CA2—esophageal cancer	0.000104	0.000637	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000103	0.000632	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000103	0.000632	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000101	0.000622	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PLCE1—esophageal cancer	9.62e-05	0.000592	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ADH7—esophageal cancer	9.62e-05	0.000592	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.51e-05	0.000585	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CA1—esophageal cancer	8.73e-05	0.000537	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	8.73e-05	0.000537	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ADH1B—esophageal cancer	8.44e-05	0.000519	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—TYMP—esophageal cancer	8.06e-05	0.000496	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CA2—esophageal cancer	7.99e-05	0.000491	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	7.84e-05	0.000483	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALOX15—esophageal cancer	7.64e-05	0.00047	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.43e-05	0.000457	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ADH7—esophageal cancer	7.43e-05	0.000457	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—TPI1—esophageal cancer	7.29e-05	0.000449	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTO1—esophageal cancer	7.29e-05	0.000449	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALDOB—esophageal cancer	6.99e-05	0.00043	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GAPDH—esophageal cancer	6.73e-05	0.000414	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CRABP1—esophageal cancer	6.67e-05	0.00041	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.51e-05	0.000401	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GNG7—esophageal cancer	6.34e-05	0.00039	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—TYMP—esophageal cancer	6.22e-05	0.000383	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.05e-05	0.000372	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALDH2—esophageal cancer	5.94e-05	0.000366	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALOX15—esophageal cancer	5.9e-05	0.000363	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTT1—esophageal cancer	5.65e-05	0.000348	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—TPI1—esophageal cancer	5.63e-05	0.000346	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.63e-05	0.000346	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	5.59e-05	0.000344	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.57e-05	0.000342	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.4e-05	0.000332	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ENO1—esophageal cancer	5.3e-05	0.000326	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTGS1—esophageal cancer	5.3e-05	0.000326	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PSME2—esophageal cancer	5.22e-05	0.000321	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PSME1—esophageal cancer	5.22e-05	0.000321	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.19e-05	0.00032	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.15e-05	0.000317	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GNG7—esophageal cancer	4.9e-05	0.000301	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.59e-05	0.000282	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.56e-05	0.00028	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	4.51e-05	0.000277	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.36e-05	0.000268	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.31e-05	0.000265	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	4.24e-05	0.000261	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ENO1—esophageal cancer	4.09e-05	0.000252	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.09e-05	0.000252	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PSME2—esophageal cancer	4.03e-05	0.000248	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PSME1—esophageal cancer	4.03e-05	0.000248	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—HMOX1—esophageal cancer	3.87e-05	0.000238	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.79e-05	0.000233	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ABCB1—esophageal cancer	3.71e-05	0.000228	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.48e-05	0.000214	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.27e-05	0.000201	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.98e-05	0.000184	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.86e-05	0.000176	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.81e-05	0.000173	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.48e-05	0.000153	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NOS3—esophageal cancer	2.22e-05	0.000137	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.03e-05	0.000125	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.91e-05	0.000118	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NOS3—esophageal cancer	1.71e-05	0.000105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—EP300—esophageal cancer	1.69e-05	0.000104	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.57e-05	9.64e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—EP300—esophageal cancer	1.3e-05	8.02e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.25e-05	7.68e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	9.64e-06	5.93e-05	CbGpPWpGaD
